Uncategorized

WASHINGTON — President Trump’s 2026 budget proposes slashing the National Institutes of Health’s central function, supporting research by awarding grants to universities, academic medical centers, and other institutions, by 43% compared to 2025 levels. New documents released by the agency show an $11.6 billion cut in this funding, to $15.1 billion, which would both reduce […]

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. A monthly treatment from Otsuka […]

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I’m back! Sorry for the unannounced break last week, but I was underwater. May was a terrible month for biotech, but June is (early days) looking better. Continue to STAT+ to read […]

When the Trump administration put a pause on student visa interviews recently, it hit a perhaps surprising group: thousands of J-1 physician visa holders who are supposed to start residency on July 1. Now, they are unsure what their future will hold. The hospitals where they are supposed to work are scrambling, too. The U.S. […]

In the first major report from the president’s Make America Healthy Again Commission, disordered eating is mentioned just once, in passing, in connection with the benefits of family meals. Amid dozens of references to obesity and a major focus on what foods American children consume, there are zero mentions of specific conditions like anorexia nervosa, […]

Kymera Therapeutics on Monday reported that an experimental drug designed to rival Sanofi and Regeneron’s blockbuster therapy Dupixent succeeded in a closely watched early-stage trial. The Phase 1 trial, which enrolled 118 healthy volunteers, tested the safety and tolerability of KT-621, a small molecule drug that targets STAT6, a signaling protein that plays a key […]

Adam Feuerstein/STAT Matthew Herper covers medical innovation — both its promise and its perils. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech […]

The Department of Health and Human Services on Friday released a summary of President Trump’s budget request for the 2026 fiscal year that provides the most detailed look yet at how his administration hopes to reshape the National Institutes of Health and other federal agencies. The “budget in brief” document doubles down on a previous […]

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. An experimental COPD medicine from Sanofi and Regeneron Pharmaceuticals produced mixed results in a pair of studies, the companies said Friday, sending both firms’ shares down in early and pre-market trading.  The drug, called itepekimab, carries […]

For the past decade, Stealth BioTherapeutics has ridden a rollercoaster trying to convince the Food and Drug Administration to approve its ultra-rare disease drug. Now, the company has encountered yet another twist — an unexpected regulatory rejection that will not only delay access and strain its finances, but ensure some of the most vulnerable patients […]